Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Please Try Again {{ error }}

Send my password

SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Breaking & Recent News Protara Therapeutics Inc. TARA

Protara Therapeutics Inc is committed to identifying and advancing transformative therapies for people with rare and specialty diseases. The Protara team prioritizes creativity, diverse perspectives and tenacity to expedite our goal of bringing life-changing therapies to people with limited treatment options. The company discovers, develops, and delivers breakthrough therapies to people who have limited treatment options. Its portfolio includes its program, TARA-002, being developed for the treatment of lymphatic malformations, and intravenous (IV) choline chloride, a phospholipid substrate replacement therapy for the treatment of intestinal failure associated liver disease (IFALD).


Recent & Breaking News (NDAQ:TARA)

Proteon Therapeutics to Present at the 17th Annual BIO CEO & Investor Conference February 9th

GlobeNewswire February 5, 2015

Journal of Cardiovascular Pharmacology Publishes Positive Nonclinical Results of Proteon Therapeutics' PRT-201 in Peripheral Artery Disease

GlobeNewswire January 8, 2015

Proteon Therapeutics to Present at the Oppenheimer 25th Annual Healthcare Conference December 11th

GlobeNewswire December 8, 2014

Proteon Therapeutics Announces Third Quarter 2014 Financial Results

GlobeNewswire November 25, 2014

Proteon Therapeutics Announces the Closing of Initial Public Offering and the Underwriters' Option to Purchase Additional Shares

GlobeNewswire November 24, 2014

Proteon Therapeutics to Present at the Stifel Nicolaus 2014 Healthcare Conference November 18th

GlobeNewswire November 17, 2014